Alivus Life Sciences Limited Reports FY 2025‑26 Results and Announces Dividend Recommendation
Alivus Life Sciences Limited, a prominent Indian‑based contract manufacturing and active pharmaceutical ingredients (API) provider, released its audited financial results for the quarter and year ended 31 March 2026 on 14 May 2026. The company, formerly known as Glenmark Life Sciences Limited until its re‑branding in December 2024, operates under the corporate umbrella of Nirma Limited and is listed on the National Stock Exchange of India (NSE) under the scrip code 543322.
Key Highlights of the 2025‑26 Performance
- Dividend Recommendation – In its board meeting held on 14 May 2026, the Board inter‑alia approved the audited financial results and recommended a final dividend for the year. The specific dividend amount and payout ratio were disclosed in the accompanying board circular, signalling management’s confidence in sustaining shareholder value.
- Financial Strength – With a market capitalisation of ₹138 201 137 152 and a price‑earnings ratio of 24.434, Alivus maintains a solid valuation relative to peers in the health‑care sector. The company’s share price as of 12 May 2026 closed at ₹1 080.80, comfortably positioned between its 52‑week low of ₹819 (21 January 2026) and high of ₹1 200 (15 May 2025).
- Global API Portfolio – Alivus continues to supply a diversified array of APIs, including cardiovascular agents (olmesartan, telmisartan), diabetes drugs (sitagliptin, remogliflozin), oncology compounds (palbociclib), and several others spanning central nervous system, respiratory, and anti‑infective indications. This breadth supports stable revenue streams across multiple therapeutic areas.
- Contract Development & Manufacturing Services – The company’s contract services remain a critical growth lever, catering to multinational pharmaceutical firms and specialty companies. Its manufacturing footprint spans India, Japan, Europe, North America, Latin America, and other international markets.
Supporting Documentation Released
Investor Presentation – Q4 & FY 2025‑26 On 14 May 2026, Alivus furnished an investor presentation outlining its financial performance, strategic initiatives, and forward‑looking outlook. This document, shared with the NSE’s Department of Corporate Services, offers detailed charts on revenue growth, gross margin trends, and capital expenditure plans.
Press Release – Q4 & FY 2025‑26 Results A formal press release dated 14 May 2026 announced the audited figures, highlighting key metrics such as revenue, operating profit, and net income. The release also addressed the company’s response to market dynamics and its stance on regulatory developments in the pharmaceutical sector.
Employee Stock Option Scheme – 2021 Alivus notified the NSE of the allotment of equity shares under its 2021 Employee Stock Option Scheme. While the exact number of shares and exercise terms were not disclosed in the brief, the intimation confirms the company’s commitment to aligning employee incentives with long‑term shareholder value.
Board Circulars on Audit and Dividend Two board circulars, dated 14 May 2026, formalised the approval of the audited results and the recommendation of the final dividend. These circulars are available to shareholders and regulatory authorities, ensuring transparency in governance.
Outlook and Strategic Focus
Alivus Life Sciences Limited is positioning itself for continued growth through several strategic pillars:
- Expansion of API Production Capacity – Investments in state‑of‑the‑art facilities will enhance output and quality compliance across its product lines.
- Diversification of Contract Services – Targeting high‑margin specialty APIs and advanced manufacturing services aims to capture a larger share of the global contract market.
- Geographic Penetration – Strengthening sales and distribution networks in emerging markets such as Latin America and Southeast Asia is expected to boost export revenues.
- Innovation Pipeline – Ongoing R&D into novel APIs, especially in oncology and metabolic disorders, will sustain the company’s competitive edge.
Conclusion
The audited financial results for FY 2025‑26 reaffirm Alivus Life Sciences Limited’s robust position within the global pharmaceutical manufacturing landscape. With a clear dividend strategy, a diversified product portfolio, and a forward‑leaning growth plan, the company continues to deliver value to shareholders while reinforcing its role as a key partner for multinational pharmaceutical enterprises.
